AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01544114
Drug: VIMOVO 500/20
RxNorm normalized name: Vimovo 500/20 Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
Trial: NCT03519867
Drug: Zemuron®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs. If needed, a maintenance dose of 0.15 mg/kg will be given. Doses are based on actual body weight.
Trial: NCT01946204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
Trial: NCT01429402
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
Trial: NCT01429402
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
Trial: NCT00798070
Drug: FEC→T
RxNorm normalized name: Fluorouracil, Epirubicin, and Cyclophosphamide followed by Paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
Trial: NCT00382018
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No administration details available
Trial: NCT04251533
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg orally, once per day (QD), tablets
Trial: NCT03913442
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.8 mg or 0.6 mg orally once daily for 3 months
Trial: NCT00784212
Drug: BGG492
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00784212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02224521
Drug: GSK2190915 Granule Capsule (A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915A granule filled in to Gelatin capsules
Trial: NCT02224521
Drug: GSK2190915 Semi-solid Lipid Capsule (B)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
Trial: NCT02224521
Drug: GSK2190915 Liquid Lipid Capsule (C)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
Trial: NCT02224521
Drug: GSK2190915 Milled Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915A granule is blended, compressed into tablets and aqueous film coated
Trial: NCT02224521
Drug: GSK2190915 Micronised Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915A granule is blended, compressed into tablets and aqueous film coated
Trial: NCT01299038
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken orally once a day for 4 weeks
Trial: NCT00312000
Drug: capecitabine-irinotecan
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~2. nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1
Trial: NCT00312000
Drug: capecitabine+irinotecan (1st line)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
Trial: NCT03629340
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
Trial: NCT04495621
Drug: MEN1611
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEN1611 oral dose administered twice daily for a continuous 28-day cycle.
Trial: NCT02160782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally once daily during randomized withdrawal period
Trial: NCT00195572
Drug: Isovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01638767
Drug: Contraceptives, Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
Trial: NCT01638767
Drug: Contraceptive, Vaginal ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
Trial: NCT03309800
Drug: HL301
RxNorm normalized name: Hydrocodone and Levorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
Trial: NCT03576885
Drug: inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled nitric oxide will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
Trial: NCT03576885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
Trial: NCT00555009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
Trial: NCT03581773
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg pr day for 12 weeks
Trial: NCT03581773
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo pill pr day for 12 weeks
Trial: NCT03337607
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks
Trial: NCT03339882
Drug: Remifemin
RxNorm normalized name: Remifemin Menopause Relief Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifemin 0.2g po bid\*12 weeks at the beginning of the LHRH-a treatment
Trial: NCT02449291
Drug: APD421
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02449291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01452529
Drug: Hydrocodone bitartrate q24h film-coated tablets
RxNorm normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
Trial: NCT01452529
Drug: Placebo to match hydrocodone bitartrate q24h tablets
RxNorm normalized name: Hydrocodone Bitartrate
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
Trial: NCT00403286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Solution for nebulization 2 mL bid for 2 weeks
Trial: NCT02884206
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan
Trial: NCT02884206
Drug: Placebo of LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
Trial: NCT00398411
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet per day p.o.
Trial: NCT00950742
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose cohorts from low dose to MTD
Trial: NCT00608205
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02668783
Drug: Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring
RxNorm normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
Trial: NCT02668783
Drug: Placebo vaginal ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 4 cycles (or 6 cycles if also participating in the extension) of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
Trial: NCT02668783
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping, or as instructed by their physician according to local labeling for relief of menstrual pain.
Trial: NCT01417897
Drug: Regular human insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
Trial: NCT01630200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
Trial: NCT00585390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil capsule
Trial: NCT00356720
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00149292
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01797120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
Trial: NCT00679523
Drug: AN2690 Solution, 5.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 180 days
Trial: NCT00679523
Drug: AN2690 Solution, 7.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for 180 days
Trial: NCT01436916
Drug: placebo + life style counselling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
Trial: NCT01795638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
Trial: NCT01613365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal and nasopharyngeal decontamination with placebo
Trial: NCT03192059
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Efficacy of the combined treatment
Trial: NCT00265551
Drug: SCA-136 (200 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00265551
Drug: SCA-136 (400 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00265551
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00063128
Drug: human insulin inhalation powder (HIIP)
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Administer HIIP within 15 minutes before meals.~* Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.~* Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin
Trial: NCT02691897
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 3mg once daily at bedtime
Trial: NCT02691897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet once daily at bedtime
Trial: NCT04467697
Drug: SOV2012-F1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral preparation of testosterone undecanoate (TU). Strengths of 100 mg TU, 150 mg TU and 200 mg TU
Trial: NCT00886665
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, 4 g, powder, oral, 3 times a day
Trial: NCT01927757
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Background methotrexate at least 15 mg weekly
Trial: NCT04480463
Drug: SCD411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVT (intravitreal) injection
Trial: NCT03540810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive placebo with their usual treatment
Trial: NCT01973569
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administered subcutaneously to match denosumab
Trial: NCT03820180
Drug: Test Product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT03820180
Drug: Reference Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT00794781
Drug: E6201
RxNorm normalized name: TRACH STOMA PROTECTOR,CLOTH WHITE BE6201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m\^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
Trial: NCT03350165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877 matching placebo tablet
Trial: NCT04028063
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin is the standard of care first-line therapy for most subtypes of metastatic soft tissue sarcomas. Doxorubicin monotherapy administered at 75 mg/m2 has resulted in objective response rate of 14%, and median progression-free survival of 4.6 months, and another study reported progression-free survival at 6 months of 46.3%, with a median PFS of 5.8 months, and best objective response rate of 19%.
Trial: NCT02601313
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT00419926
Drug: Enteric-coated mycophenolate sodium (Myfortic)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
Trial: NCT03745625
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h.
Trial: NCT01460251
Drug: DiaPep277
DrugBank: DiaPep 277 (DB06651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
Trial: NCT02556203
Drug: Acetylsalicylic Acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75-100mg OD
Trial: NCT02556203
Drug: Vitamin K antagonist (VKA)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
Trial: NCT03980379
Drug: 304 injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies, 100mg/10ml per injection
Trial: NCT00528827
Drug: Cardene® I.V.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V.
Trial: NCT00176787
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01818570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
Trial: NCT03967795
Drug: N2-L-Alanyl-L-Glutamine (Substance)
RxNorm normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
Trial: NCT02350530
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Trial: NCT02600169
Drug: Pemprolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.
Trial: NCT00092859
Drug: MK0557
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03892785
Drug: Methotrexate treatment
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate subcutaneous from W0 to W51 (52 administrations).~* W0: 7.5 mg/week~* W1: 0.2 mg/Kg/week~* W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51
Trial: NCT01937364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
Trial: NCT06224582
Drug: Yinxingmihuan oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yinxingmihuan oral solution is made of Ginkgo leaf extract and armillariella mellea powders.
Trial: NCT04131413
Drug: pNGVL4aCRTE6E7L2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose escalation will start from the lowest dose level of 0.3 mg. This dose cohort will consist of 3 participants and a monitoring period of one week after the final dose mandated. If there are 0 participants in the 0.3 dose level cohort that experience dose limiting toxicities (DLT), a new cohort of 3 participants will be vaccinated at the 1.0 mg dose level. If there are 0 participants in the 1.0 mg dose level that experience DLT, then a new cohort of 3 participants will be vaccinated at the 3.0 mg dose level. If there is 1 participant experiencing DLTs, an additional cohort of 3 subjects will be enrolled and treated at the current dose level. If there are 2 or more participants experiencing DLTs in the 3 or additional cohort of 3 vaccinated at the current dose level, then the next lower dose level will be determined as the Maximum Tolerated Dose (MTD).
Trial: NCT04159415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).
Trial: NCT04159415
Drug: High-dose REGN4461
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion loading dose or SC injection QW.
Trial: NCT06224582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo oral solution is in the same appearance, color, smell and taste as the experimental Yinxingmihuan oral solution.
Trial: NCT04171765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.
Trial: NCT04171765
Drug: BFKB8488A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous (SC) BFKB8488A.
Trial: NCT02503423
Drug: ASTX660
FDA approved: no
EMA approved: no
PMDA approved: no
Description: described above
Trial: NCT01439100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy tablet
Trial: NCT03198078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily, tablets
Trial: NCT00691067
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo